JCAD, a New Potential Therapeutic Target in Cholestatic Liver Disease
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances.
Xie L, Zhang L, Chen H, Yang Y, Wu J Clin Mol Hepatol. 2024; 30(2):279-280.
PMID: 38503552 PMC: 11016501. DOI: 10.3350/cmh.2024.0191.
References
1.
Tanaka A
. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2020; 27(1):1-21.
PMC: 7820210.
DOI: 10.3350/cmh.2020.0028.
View
2.
. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017; 67(1):145-172.
DOI: 10.1016/j.jhep.2017.03.022.
View
3.
Heo N, Kim H
. Epidemiology and updated management for autoimmune liver disease. Clin Mol Hepatol. 2022; 29(1):194-196.
PMC: 9845658.
DOI: 10.3350/cmh.2022.0387.
View
4.
Jones P, Kaiser M, Najafabadi M, Koplev S, Zhao Y, Douglas G
. JCAD, a Gene at the 10p11 Coronary Artery Disease Locus, Regulates Hippo Signaling in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2018; 38(8):1711-1722.
PMC: 6296439.
DOI: 10.1161/ATVBAHA.118.310976.
View
5.
Zhao Y, Wei S, Chen L, Zhou X, Ma X
. Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products. Front Immunol. 2023; 14:1164202.
PMC: 10349375.
DOI: 10.3389/fimmu.2023.1164202.
View